Oxygen gradient ektacytometry-derived biomarkers are associated with acute complications in sickle cell disease

Minke A. E. Rab, Celeste K. Kanne, Camille Boisson, Jennifer Bos, Brigitte A. van Oirschot, Maite E. Houwing, C. line Renoux, Marije Bartels, Anita W. Rijneveld, Erfan Nur, Marjon H. Cnossen, Philippe Joly, Elie Nader, Romain Fort, Philippe Connes, Richard van Wijk, Vivien A. Sheehan, Eduard J. van Beers

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

We investigated the potential of the point of sickling (PoS; the pO2 tension at which red cells start to sickle), determined by oxygen gradient ektacytometry to serve as a biomarker associated with the incidence of acute sickle cell disease-related complications in 177 children and 50 adults. In the pediatric cohort, for every 10 mmHg increase in PoS reflecting a greater likelihood of sickling, the likelihood of an individual experiencing >1 type of acute complication increased; the adjusted odds ratio (aOR) was 1.65. For every 0.1 increase in minimum elongation index (EImin; reflecting improved red blood cell deformability at hypoxia), the aOR was 0.50. In the adult cohort, for every 10 mmHg increase in PoS, we found an aOR of 3.00, although this was not significant after correcting for multiple testing. There was a trend for an association between higher PoS and greater likelihood of vaso-occlusive episodes (VOEs; children aOR, 1.35; adults aOR, 2.22). In children, only EImin was associated with VOEs (aOR, 0.68). When data of both cohorts were pooled, significant associations with PoS and/or EImin were found for all acute complications, independently and when >1 type of acute complication was assessed. These findings indicate that oxygen gradient ektacytometry generates novel biomarkers and provides a rationale for further development of these biomarkers in the assessment of clinical severity, evaluation of novel therapies, and as surrogate clinical trial end points. These biomarkers may be useful in assessing efficacy of novel therapies like pyruvate kinase activators, voxelotor, and Lglutamine.
Original languageEnglish
Pages (from-to)276-286
Number of pages11
JournalBlood advances
Volume8
Issue number2
DOIs
Publication statusPublished - 23 Jan 2024

Cite this